ArticleCureus2025
Bone Marrow Failure in Prostate Cancer: A Rare Case Initially Disguised as Thrombotic Thrombocytopenic Purpura.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the second most common cause of cancer-related death and the leading cause of new cancer cases in men in the United States. Bone trabeculae are the most common site of metastasis for prostate cancer, but bone marrow (BM) involvement is rare. Around six percent of patients with new metastatic castrate-sensitive prostate cancer (mCSPC) have biopsy-proven BM metastasis. We present a case of mCSPC with BM metastasis initially disguised as thrombotic thrombocytopenic purpura (TTP). Initial presentation revealed anemia and thrombocytopenia with a peripheral blood smear indicating thrombotic microangiopathy. Empiric treatment for TTP was initiated, but the patient showed no improvement. A BM biopsy performed on hospital day 5 for further work-up of the refractory cytopenias eventually identified metastatic prostate adenocarcinoma. The patient started androgen deprivation therapy, but attempts at follow-up care were unsuccessful. The patient passed away five months later. This case highlights the diagnostic complexity of cytopenias and contributes to our understanding of BM-metastatic prostate cancer. BM involvement in mCSPC complicates prognosis, and further research into its pathophysiology and targeted therapies is needed to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.